Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antibacterial
    (1)
  • Drug Metabolite
    (1)
  • EGFR
    (1)
  • Others
    (6)
Filter
Search Result
Results for "

ag-18

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
  • Recombinant Protein
    7
    TargetMol | Recombinant_Protein
Tyrphostin 23
Tyrphostin A23, TX 825, RG-50810, AG18
T2063118409-57-7
Tyrphostin 23 (AG18) inhibits EGFR with IC50 of 35 μM.
  • Inquiry Price
Size
QTY
AG-183
T21783122520-90-5
(Z)-Tyrphostin A51, the Z configuration of Lanoconazole A51, is a potent protein tyrosine kinase (PTK) inhibitor that dose-dependently inhibits the volume-sensitive release of [3 H]taurine in primary astrocyte cultures. It significantly reduces cellular tyrosyl phosphorylation levels and inhibits both basal and EGF-induced human bone cell proliferation [1] [2].
  • Inquiry Price
6-8 weeks
Size
QTY
AG-1859
AG 001859,AG 1859,AG-001859,AG001859
T26571478410-84-3
AG-1859, an HIV protease inhibitor, is used potentially for the treatment of HIV infection.
  • Inquiry Price
6-8 weeks
Size
QTY
AG-1801
UNII-WYN000A4MH,AG1801,AG 1801
T29703204010-55-9
AG-1801 is a bio-active chemical.
  • Inquiry Price
Size
QTY
AG-1812 free base
UNII-6RI44GB0V9, Lansoprazole disulfide active metabolite, HE078804, AC1MIZB6
T29704700341-80-6
ABT-1812 is a bio-active chemical.
  • Inquiry Price
Size
QTY
Lansoprazole sulfide
AG-1777, AG1777
T21128103577-40-8
Lansoprazole sulfide (AG-177) is an active metabolite of Lansoprazole with similar activity.Lansoprazole is a proton pump inhibitor and antitubercular agent with an IC50= 0.59 µM against Mycobacterium tuberculosis.
  • Inquiry Price
7-10 days
Size
QTY
AG-012986
T69196486414-35-1
AG-012986 is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4 6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 showed antiproliferative activities in vitro with IC(50)s of <100 nmol L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 also showed dose-dependent retinoblastoma Ser(795) hypophosphorylation, cell cycle arrest, decreased Ki-67 tumor staining, and apoptosis in conjunction with antitumor activity.
  • Inquiry Price
6-8 weeks
Size
QTY
AG-012986 HCl
T69197486414-32-8
AG-012986 HCl is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4 6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 HCl showed antiproliferative activities in vitro with IC(50)s of <100 nmol L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 HCl was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 HCl also showed dose-dependent retinoblastoma Ser(795) hypophosphorylation, cell cycle arrest, decreased Ki-67 tumor staining, and apoptosis in conjunction with antitumor activity.
  • Inquiry Price
6-8 weeks
Size
QTY